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Abstract The  Weld of tumor vaccination is currently
undergoing a shift in focus, from individualized tailor-made
vaccines to more generally applicable vaccine formula-
tions. Although primarily predicated by Wnancial and logis-
tic considerations, stemming from a growing awareness
that clinical development for wide-scale application can
only be achieved through backing from major pharmaceuti-
cal companies, these new approaches are also supported by
a growing knowledge of the intricacies and minutiae of
antigen presentation and eVector T-cell activation. Here,
the development of whole-cell tumor and dendritic cell
(DC)-based vaccines from an individualized autologous
set-up to a more widely applicable allogeneic approach will
be discussed as reXected by translational studies carried out
over the past two decades at our laboratories and clinics in
the vrije universiteit medical center (VUmc) in Amsterdam,
The Netherlands.
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Autologous whole-cell tumor vaccination
Autologous tumor cells are an obvious source of tumor-
associated antigens (TAA) for vaccination purposes, since,
by deWnition, all relevant candidate TAA should be con-
tained within them. Vaccination with irradiated tumor cells
has been studied in various animal models as early as the
1970s. Pioneered by Hanna et al. irradiated hepatocellular
carcinoma cells were used as a vaccine in a guinea pig
model and, admixed with bacillus calmette-guérin (BCG)
as an immune adjuvant, were found to generate protective
immunity against subsequent challenge with syngeneic
non-irradiated tumor cells [17,  18]. Of note, these early
guinea pig studies revealed the importance of vaccinating
with live tumor cells, suggesting either a) the direct
involvement of the tumor cells themselves in antigen pre-
sentation or b) the importance of prolonged expression and
release of TAA to allow for suYcient uptake by and activa-
tion of immune eVector cells. Before general acceptance of
the concept of cross-priming, the former was actually
regarded as the more obvious explanation.
Colorectal cancer
Building on this pre-clinical work, Hoover et al. conducted
a clinical trial in which patients with stage II/III colorectal
cancer were vaccinated with irradiated autologous tumor
cells and BCG, randomized versus surgery alone [24]. Sub-
group analysis revealed signiWcant overall and disease-free
survival for vaccinated patients. In addition, delayed type
hypersensitivity (DTH) reactions to autologous tumor cells
suggested the presence of tumor-speciWc immunity. Side
eVects were minimal and consisted mostly of ulceration of
the vaccination sites caused by the BCG adjuvant.These
promising results prompted the initiation of a large phase
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III study of stage II/III colon cancer patients conducted
under the auspices of the eastern cooperative oncology
group (ECOG) [20]. This study diVered from the Hoover
study in that, due to the large number and wide geographic
distribution of participating sites, each site manufactured its
own vaccines. In an intent-to-treat analysis of all random-
ized patients, no signiWcant diVerences were observed
between the two treatment arms in time to recurrence or
overall survival. In the ECOG study, 12% of all vaccines
failed to meet quality control speciWcations (in terms of cell
number and/or viability), and 15% of the vaccinated
patients failed to develop DTH reactions to tumor cells
alone. Importantly, DTH reactivity to autologous tumor
cells did correlate with survival [20]. It was therefore
assumed that poor quality of a part of the vaccines and var-
iability introduced by manufacture at diVerent sites were at
the root of the disappointing clinical results of this study.
Indeed, survival analysis of patients who were treated with
vaccines that met standardization criteria and who actually
developed anti-tumor immunity (as determined by DTH
reactivity) did show a signiWcant improvement in overall
survival. These Wndings underlined the necessity of stan-
dardized vaccine manufacture to make any meaningful
comparisons in outcome between vaccinees: a particular
challenge in an autologous set-up.
A third phase III study was conducted at our laboratory
in the VUmc, involving 254 patients with stage II/III colon
cancer [62]. This pivotal study diVered from the previous
ECOG study in that a centralized manufacturing laboratory
(i.e.the VUmc) supported the 12 participating hospitals,
resulting in 98% quality approved vaccines and a rate of
97% measurable DTH reactivity upon vaccination (i.e. >5
mm). In an intent-to-treat analysis, autologous tumor cell +
BCG vaccination signiWcantly reduced the rate of disease
recurrence by 44% in patients with stage II/III colon cancer,
but the overall survival was not signiWcantly aVected. A
larger impact was apparent in stage II disease, where a 61%
risk reduction for recurrences and a trend toward improved
overall survival was observed. These data clearly indicate
that the centralized and routine manufacture of quality-
controlled vaccines is of the utmost importance for the
performance of a successful immunization trial.
A meta-analysis was performed which included the
above described three randomized trials for colorectal can-
cer [19]. In the intent-to-treat meta-analysis of all 723
patients who received either a three- or a four-vaccine regi-
men, recurrence-free survival was signiWcantly improved
by autologous whole-cell tumor vaccination. However, no
signiWcant overall survival beneWt could be demonstrated.
While these studies showed promise, more recent FDA
prerequisites have complicated the production and quality
assurance of these autologous whole-cell tumor based vac-
cines for colon cancer. Particularly sterility requirements
are posing a considerable challenge for an autologous
whole-cell vaccine derived from an organ as rife with com-
mensal bacteria as the colon. These restrictions were
enforced despite the fact that empirically, in over 200 vac-
cinated patients, these colon-associated bacteria (whether
admixed with BCG or not) were never found to cause any
untoward side eVects. These regulatory hurdles, combined
with Wnancial restraints, have led to the premature termina-
tion of a Phase III trial carried out in our clinics at the
VUmc, studying the eVect of whole-cell colon tumor vacci-
nation combined with 5-FU chemotherapy versus chemo-
therapy only, in patients with Stage III colon cancer.
Melanoma
Fostering the autologous whole-cell vaccine + BCG
approach, a clinical study was performed at the VUmc
with 81 stage III/IV metastatic melanoma patients [1].
Forty-nine of these patients had no sign of residual disease
after metastasectomy, although the chances of tumor
recurrence were considered high. After metastasectomy
whole-cell tumor vaccines were produced of the resected
tumor tissue. One month after surgery the Wrst of three
weekly administered irradiated vaccines was administered
intradermally in one of the lower extremities. In patients
with evidence of disease during the vaccination period
(n = 38) no clinical responses occurred and no survival ben-
eWt was apparent when compared to historical controls. In
patients without evidence of disease (stage III, n = 35 and
stage IV, n = 14), the 5-year overall survival rate approxi-
mated 45%, which was superior to historical controls (at
35% and 20% for Stage III and IV, respectively) [1]. In
addition, DTH reactivity to tumor cells was found to corre-
spond positively with overall survival [1]. Finally, this
study revealed that the size of DTH-reactions waned after
consecutive non-BCG-containing vaccinations, even in
patients that after a follow-up period of over Wve years
proved to be free of melanoma. This observation strongly
suggests that booster vaccinations can only be eVective
when co-administered with an immunostimulating adju-
vant.
Berd et al. also developed and clinically tested an autolo-
gous melanoma cell vaccine, haptenated with dinitrophenyl
(DNP), and also combined it with BCG as adjuvant [3].
After an inclusion period of more than 10 years they
reported a 5-year relapse free survival of 33% and an over-
all survival of 44% for a non-randomized trial with 214
enrolled stage III melanoma patients. These survival rates
were considered superior to historical control survival data.
Of note, they also observed an association of overall sur-
vival and disease free survival with the induction of DTH
reactivity to unmodiWed (non-haptenated) autologous mela-
noma cells [3].Cancer Immunol Immunother (2008) 57:1569–1577 1571
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Renal cell cancer
In a large multi-center Phase III trial carried out in Ger-
many, 558 patients with a renal cell tumor were pre-opera-
tively randomized to receive either six monthly intradermal
autologous tumor vaccines or no adjuvant therapy [30].
Tumor cells were pre-treated with IFN- to upregulate
MHC levels and underwent six freeze-thaw cycles prior to
administration. No further immune adjuvants were added to
the vaccines. 5-year progression-free survival was 77.4%
in the vaccinated patients as compared to 67.8% in the
untreated patients. Although promising, these results might
have been improved upon through the inclusion of a strong
immune adjuvant in the vaccine formulation. Although
BCG proved its worth as immune adjuvant, the resulting
ulcers at vaccination sites eventually disqualiWed it as the
adjuvant of choice for cancer vaccination. The identiWca-
tion of hypomethylated CpG sequences derived from bacte-
rial DNA as the immune-activating component of BCG
[31, 32] led to the design of a Phase II trial at the VUmc
in which patients with advanced Renal Cell Cancer were
vaccinated with an autologous whole-tumor cell vaccine
admixed with a combination of CpG (type-B, PF-3512676),
IFN, and Granulocyte-Macrophage Colony-Stimulating
Factor (GM-CSF) as adjuvant. The Wrst three induction
vaccinations were given weekly followed by subcutaneous
administration of IFN- (6 MIU) and PF-3512676 (8 mg bi-
weekly). After 3 months tumor evaluation was performed
and in case of a remission or stable disease patients contin-
ued with 3 monthly vaccinations and PF-3512676/IFN-.
This vaccination schedule resulted in a 20% clinical
response rate in association with a strong anti-tumor DTH
skin reactivity [59]. This study clearly showed the equiva-
lence of this adjuvant combination to BCG in terms of
immune activation, without the ulcer formation usually
associated with BCG.
GVAX: from autologous towards allogeneic tumor 
vaccination
GM-CSF is a 23-kDa glycoprotein that was initially devel-
oped for its activity as a hematopoietic growth factor [52].
Subsequent studies revealed its interesting immunological
features [8,  10]. GM-CSF can overcome tumor-induced
immune suppression and promotes the recruitment and
maturation of specialized antigen-presenting cells (APC).
GM-CSF-mediated activation of APC results in upregula-
tion of MHC class II, co-stimulatory molecules and cyto-
kine production. It increases antibody responses and
cellular immunity after immunization.These combined fea-
tures have made GM-CSF the most commonly used cyto-
kine to boost anti-tumor immunity [8, 10, 29]. In a murine
melanoma model DranoV et al. demonstrated the potency
of prophylactic GM-CSF-transduced autologous tumor cell
vaccines in prevention of tumor outgrowth [9]. Based on
this preclinical work, autologous melanoma tumor cells,
transduced with GM-CSF (GVAX), were applied clinically
and shown to induce tumor-speciWc immunity and durable
anti-tumor responses in a number of trials [22].
Mouse studies clearly demonstrated the eYcacy of
GVAX to depend on the cross-presentation of vaccine-
derived TAA to speciWc cytotoxic T lymphocytes (CTL) in
vivo [22]. This process of cross-priming is facilitated by the
activation of professional APC, the so-called Dendritic
Cells (DC), by GM-CSF. This Wnding led to the realization
that allogeneic cells would also present a viable source of
TAA, which would be taken up by DC and then presented
in the context of appropriate MHC alleles to autologous
CTL. Advantages to the use of allogeneic cells are obvious:
(1) through the use of antigenically well-deWned cell lines
one has access to a sustained and virtually limitless source
of TAA, (2) the use of cell lines allows for the highly stan-
dardized and large-scale production of allogeneic vaccines,
(3) the use of a single batch of allo-vaccines for all vaci-
nees, independent of HLA haplotype, eliminates variability
in the quality and composition of the vaccines and facili-
tates reliable comparative analysis of clinical outcome, and
(4) eliminating the need for the continuous production of
tailor-made individual vaccines simpliWes the logistics and
reduces the laboriousness of the vaccine production and
delivery process and increases its cost-eVectiveness.
Taking these considerations into account, autologous
GVAX approaches have been replaced by allogeneic GVAX
formulations. JaVee et al. tested an allogeneic pancreatic
cancer vaccine as an adjuvant therapy after pancreaticoduo-
denectomy in a phase I dose-escalating study and found no
noteworthy toxicity, while some patients showed increased
DTH-skin reactivity to autologous tumor cells, indicative of
the generation of relevant anti-tumor immunity [28].
Prostate cancer
Michael et al. showed the feasibility of allogeneic prostate
cancer vaccination: vaccines consisting of three prostate
tumor cell lines were i.d. injected monthly over the course
of a year in patients with hormone refractory prostate can-
cer [35]. The Wrst two vaccines were admixed with BCG.
Decreases in PSA velocity were observed in 11/26 patients
with an overall median time to disease progression of 58
weeks as compared to 28 weeks in historical controls. Inter-
estingly, while non-responders showed a mixed Th1/Th2
response upon restimulation with a vaccine lysate, respond-
ers showed a Th1 cytokine release proWle.
Prostate GVAX consists of two prostate cancer cell lines,
LNCaP and PC-3, each of which has been genetically modiWed1572 Cancer Immunol Immunother (2008) 57:1569–1577
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to secrete GM-CSF. Following manufacture of the
transduced cell lines, the cells are lethally irradiated to pre-
vent further cell division upon vaccination. In phase I/II
studies the vaccine was generally well tolerated and demon-
strated anti-tumor activity [11, 44, 46]. The largest of these
was a multi-center phase I/II trial in 55 patients with HRPC
[46]. Thirty-four patients with metastases showed an overall
median survival of 26 months, which compares favorably
with median survival times observed in phase II taxane che-
motherapy trials in similar patients with HRPC [37, 42, 46].
Induction of sero-immune reactivity against the prostate
cancer cells was demonstrated by Western blot. A smaller
phase I/II trial was carried out in hormone therapy-naive
patients with a prostate-speciWc antigen (PSA) relapse fol-
lowing radical prostatectomy and absence of radiological
metastases [44]. Treatments were administered weekly via
intradermal injections of Prostate GVAX for 8 weeks.
Twenty-one patients were enrolled and treated. Toxicities
included local injection-site reactions, pruritus, and Xu-like
symptoms. At 20 weeks post Wrst treatment, 16 of 21 (76%)
patients showed a statistically signiWcant decrease in PSA
velocity compared with pre-vaccination (P < 0.001) [44].
Clinical eYcacy of Prostate GVAX is currently tested in
metastatic prostate cancer patients in two phase III random-
ized studies (VITAL-1 and -2). In the Wrst study GVAX is
compared to Docetaxel plus prednisone and in the second
study GVAX in combination with docetaxel is compared to
docetaxel alone. The results are eagerly awaited.
While GVAX monotherapy has shown moderate clinical
eYcacy, this may be improved upon through interference
with checkpoints at the T-cell level that under normal
circumstances serve to reinforce tolerance but that in
tumor-conditioned environments may suppress appropriate
anti-tumor immune responses. The CTL Antigen-4 (CTLA-4)
receptor represents such a crucial checkpoint [12]. It is
expressed on activated T-cells and binds to CD86 and
CD80 on DC with higher avidity than its competitor ligand
CD28. In contrast to CD28, CTLA-4 relays inhibitory sig-
nals to the T cell and blocks activating signals originating
from CD28-CD86/CD80 interactions. CTLA-4 blockade
breaks through inhibitory feedback loops in tumor-speciWc
T-cells and may thus lead to expansion of eVector CTL
with possibly a higher functional avidity [12]. In mouse
tumor models, the combination of GM-CSF-secreting vac-
cines and CTLA-4-blocking antibodies has resulted in
improved anti-tumor immunity and protection from tumor
outgrowth. Both in the B16 melanoma model and in
TRAMP, a transgenic murine model of spontaneously aris-
ing prostate cancer, the administration of either anti-CTLA-
4 mAbs or vaccination with GM-CSF transfected tumor
cells had minimal to no eVect on tumor rejection. In marked
contrast, treatment with the combination of anti-CTLA-4
and GM-CSF-transduced tumor cells at the time of tumor
inoculation signiWcantly reduced tumor incidence [26, 60,
61]. This anti-tumor eVect was shown to be CTL-mediated
and T helper cell (Th) independent, and indicates that
CTLA-4 blockade can lower the threshold of required acti-
vating signals such that Th-mediated activation of DC is no
longer needed for the provision of a “license to kill” to CTL
[61]. While Phase I/II clinical trials studying monotherapy
with either Prostate GVAX or anti-CTLA-4, have shown
feasibility of treatment with either modality without severe
side-eVects and with modest signs of possible clinical
eYcacy [11, 44, 46, 47], the aforementioned pre-clinical
studies clearly demonstrated a potentially increased
eYcacy of anti-CTLA-4 as part of a combinatorial
approach with Prostate GVAX. This led to the initiation of
a Phase I clinical study in the VUmc, in which chemo-naive
patients with metastatic hormone refractory prostate cancer
(HRPC) receive the allogeneic prostate GVAX immuno-
therapy combined with infusions of ipilimumab/anti-
CTLA-4. This trial represents the Wrst clinical application
of the GVAX/anti-CTLA4 combination. In the dose escala-
tion part of this trial, the combination of GVAX immuno-
therapy with high doses of ipilimumab (3 or 5 mg/kg) has
led to promising clinical results with some clear PSA
responses [16]. The trial has now entered its expansion
phase with an accrual of 16 patients to be treated at the
MTD of ipilimumab, determined in the escalation phase to
be 3 mg/kg. To demonstrate immune eVects of this treat-
ment and possibly correlate these with clinical eYcacy, we
are extensively monitoring dendritic and T-cell functions.
The results may aid in the rational design of clinical follow-
up studies. Final analysis will be performed after conclud-
ing the expansion phase of this Phase I trial.
DC-based tumor vaccination: the case for an allogeneic 
source of DC
DC are uniquely able to initiate primary immune responses.
Myeloid DC diVerentiate from CD34+ hematopoietic pro-
genitor cells (HPC) and can develop into two recognized
subsets, Langerhans Cells (LC, expressing the characteristic
C-type Lectin Langerin and containing Birbeck Granules
[BG]), which are mostly found in stratiWed epithelia, and
Interstitial DC (IDC, expressing the C-type Lectin DC-
SIGN), which are mostly located in connective tissues.
Because of their critical role in orchestrating the immune
response, DC are now widely applied in vaccines for the
treatment of cancer [4]. So far, the vast majority of clinical
vaccination trials utilized Monocyte-derived DC (MoDC,
i.e. IDC equivalents), while only few trials have made use of
DC derived from CD34+ precursors (CD34-DC [4]). Never-
theless, it has been suggested that CD34-DC are more eVec-
tive anti-tumor T-cell inducers than MoDC, both in vitro andCancer Immunol Immunother (2008) 57:1569–1577 1573
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in clinical DC vaccination studies [2, 14]. This favorable
eVect might be due to “contaminating” LC in the CD34-DC
preparations [38]. DC may be pulsed with TAA-derived epi-
topes in various ways: through loading with proteins or pep-
tides, through incubation with tumor lysates or apoptotic
bodies, through fusion with tumor cells, through transfection
with DNA or RNA, or through viral transduction. In various
trials anti-tumor immunity as well as clinical eYcacy of DC-
based tumor vaccination have been reported, particularly for
melanoma [33]. So far, wide-scale implementation has
proven to be unattainable for any of the tested DC-based
vaccines. A case in point was recently provided by sipuleu-
cel-T (APC8015), which consists of a DC-like fraction
enriched from autologous peripheral blood, pulsed with a
prostate TAA/GM-CSF fusion protein. Despite a favorable
survival beneWt in a randomized Phase III trial of 225
patients with metastatic prostate cancer [45] and an initial
positive verdict on safety and clinical eYcacy from an FDA
advisory committee, it was denied FDA approval, just fall-
ing short of becoming the Wrst FDA-approved cell-based
vaccine product [15]. The FDA decision letter called for
additional proof of clinical eYcacy from an ongoing ran-
domized Phase III trial (a new interim analysis of which is
expected mid-2008) and more detailed information on the
manufacturing process [15, 63]. Certainly, multiple hurdles
are to be taken in the development of such autologous DC
precursor-based immunotherapies as they are: (a) hard to
standardize, resulting in highly variable results, complicat-
ing the evaluation of clinical trials, and often resulting in
negative clinical trial outcomes, (b) laborious and time con-
suming, and therefore c) very expensive [33]. These draw-
backs have thusfar precluded wide-scale application of
autologous DC-based vaccines. In addition, although
conXicting reports exist on this matter, there have been
indications for an inferior T-cell-stimulatory phenotype of
DC derived from advanced cancer patients [21, 36], which
would also argue against the use of autologous DC.
An alternative approach which has recently been
explored is the use of allogeneic DC as vaccine vehicles. A
major advantage of the use of alloDC is the feasibility of
preparing large clinical-grade batches that may be used for
all patients, thus providing a more standardized DC vaccine
in terms of phenotype and maturation status. As with allo-
geneic tumor cell-based vaccines, bypassing the need for
individually prepared vaccines represents a considerable
logistic advantage. Although seemingly counter-intuitive,
from a theoretical point of view alloDC-based vaccines
might even induce a stronger vaccine-speciWc immune
response than autoDC [13]. Since an estimated 1–10% of
the circulating T cell repertoire is directed against allo-anti-
gens, alloDC may be expected to trigger a broadly reactive
T-cell response with two possible advantages: (1) activa-
tion of tumor-reactive T-cells through fortuitous cross-reac-
tivity and (perhaps more likely and more importantly:) (2)
allo-antigens on the DC may provide T helper (Th) epitopes
aiding in the optimal activation of Cytotoxic T Lympho-
cytes (CTL) against the tumor-related vaccine payload [13].
Several mouse studies have compared the use of alloDC
versus syngeneic DC as fusion partners for syngeneic tumor
cells, creating a DC-tumor hybrid vaccine, and consistently
shown equal or even superior protection against tumor
outgrowth with alloDC [43, 48, 51,  58]. The anti-tumor
responses were mostly shown to be CTL-mediated. Mecha-
nistically, observed advantages of the use of alloDC hybrids
seemed to be related to skewing towards a type-1 cytokine
response as compared to the use of syngeneic DC [43, 48, 58].
Various clinical trials have been carried out to validate
the use of alloDC-based tumor vaccination and results so far
have been mixed [23, 27, 36, 50, 55–57]. In these studies
patients with metastatic RCC, with melanoma, or with early-
stage B-cell chronic lymphocytic leukemia were vaccinated
with alloDC, either loaded with tumor lysates or apoptotic
bodies, or fused to autologous or allogeneic tumor cells. All
studies showed the tolerability and safety of this approach,
with some partial clinical responses, accompanied by evi-
dence of tumor-speciWc T-cell activation. On the whole,
alloDC based vaccines appeared less eVective than autolo-
gous DC used in previous trials. This might be due to a lack
in HLA class I matching [55, 56]. Of note, most favorable
results in murine models were obtained with “semi-alloge-
neic” DC, i.e. alloDC that were partially MHC-matched
[58]. While allo-MHC class II molecules may provide bene-
Wcial Th activity, it is likely that for a CTL response to be
induced, at least partial MHC class I matching is required.
This was recently conWrmed by a vaccination study in colo-
rectal cancer patients, showing that tumor lysate-loaded DC
with one haplotype miss-match induced stronger anti-tumor
immune responses, accompanied by stabilized or reduced
CEA serum levels, as compared to fully autologous DC [50].
Similarly, vaccination with autologous melanoma/alloDC
hybrids, which per deWnition would present TAA peptides in
the context of matched (in this case autologous) HLA class I
molecules, resulted in clinical responses, long survival
times, and high-frequency post-vaccination T cell responses
against a broad range of melanoma epitopes [55, 57]. These
studies clearly demonstrate the feasibility of generating
TAA-speciWc T-cell responses in vivo on an allo-back-
ground: anti-tumor responses were quite clearly not
drowned out by collateral allo-T-cell responses.
The MUTZ-3 cell line: a sustainable source of alloDC 
for vaccination purposes
While CD34-DC may be more powerful vaccine vehicles
than the more commonly used MoDC, the use of in vitro1574 Cancer Immunol Immunother (2008) 57:1569–1577
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generated CD34-DC is complicated by the lenghty and
laborious methodologies involved, considerable functional
and phenotypic variability between batches (both intra- and
inter-individual) and the extremely low frequency of
CD34+ DC precursor cells in peripheral blood. A human
CD34+ DC line would be an attractive alternative, allowing
the preparation of large quantities of standardized alloDC
that would provide an oV-the-shelf alternative for autolo-
gous DC-based tumor vaccination purposes. Over the past 8
years we have gathered evidence that the cytokine-depen-
dent CD34+ human acute myeloid leukemia (AML) cell
line MUTZ-3 represents such a sustainable supply of DC
[34, 39–41]. By matching for the HLA-A2 and/or -A3 alle-
les (both present on MUTZ–3), >50% of patients should be
eligible for MUTZ-3-based vaccination regimens.
MUTZ-3 is a heterogeneous AML cell line consisting of
CD34+ and CD14+ cell populations [25]. CD34+ MUTZ-3
cells behave as the immortalized equivalents of CD34+ DC
precursor cells [34,  40]. Upon stimulation with speciWc
cytokine cocktails, CD34+ MUTZ-3 progenitors pass
through a CD14+ state, lose their proliferative capacity, and
acquire a phenotype consistent with either classic IDC or LC
with respective characteristic and mutually exclusive
expression of DC-SIGN or Langerin and Birbeck Granules
[40]. MUTZ3-DC display the full range of functional MHC-
and CD1d-mediated antigen processing and presentation
pathways and upon maturation (induced by cocktails com-
prising IL-6, PGE2, TNF-, IL-1, IFN-, or Poly:IC) up-
regulate co-stimulatory molecules, express CD83, and dis-
play an enhanced allogeneic T-cell priming ability in mixed
leukocyte reactions (MLR) [34, 40]. By extensive functional
characterization of MUTZ3-DC (diVerentiated to either IDC
or LC), we aimed to elucidate their ability to induce a spe-
ciWc T-cell response and to serve as a clinical vehicle of
tumor vaccines [39,  41]. The lymph node (LN) homing
potential of MUTZ3-DC was conWrmed in a trans-well
assay in response to the LN-derived chemokines CCL19 and
CCL21 and shown to be comparable to MoDC [41]. This is
in line with their CCR7 expression and suggestive of their in
vivo ability to reach the paracortical T-cell areas of LN. We
demonstrated that functional (i.e. tumor-recognizing) CTL
clones could be generated against multiple tumor-associated
epitopes (derived from MART-1, CEA, Her-2/neu, and
PSA) by stimulating CD8+ CTL precursors with peptide-
loaded allogeneic, HLA-A2-matched MUTZ3-DC (both
IDC and LC) [39, 41]. Importantly, a consistent induction
capacity, as determined by MHC tetramer (Tm) binding,
was found in multiple donors (i.e. across a range of allo-
MHC haplotypes) and at an eYciency comparable to autolo-
gous peptide-loaded MoDC. TAA-speciWc CTLs generated
by MUTZ3-DC were of low-to-intermediate functional
avidity. Retroviral transduction with IL-12p70 signiWcantly
improved CTL priming eYciency of both MUTZ-3-derived
IDC and LC and resulted in priming of MART-1 speciWc
CTL with higher functional avidity, a more deWned mem-
ory-eVector phenotype, and a higher cytolytic potential for
MART-1-expressing melanoma cells [41].
Planned clinical trials are expected to demonstrate the
eYcacy of allo-DC cell lines in the in vivo priming of spe-
ciWc eVector T-cells in the face of an ongoing competition
with simultaneously primed allogeneic T-cells. It will be of
particular interest to establish the number of eVective
booster vaccinations that can be administered following the
prime vaccination, before allogeneic responses become too
restrictive and alternative vaccine formulations may have to
be applied in alternating prime-boost approaches.
The future: from whole-cell vaccines to DC-targeted 
vaccines?
While currently explored allogeneic approaches in whole
tumor cell and/or DC-based vaccination procedures repre-
sent an improvement in terms of standardization and cost
eVectiveness over their autologous counterparts, they nev-
ertheless entail the culture of large batches of cells under
cGMP conditions. It is clear that further optimization of
these in vitro culture methodologies is required to improve
therapeutic eYcacy of DC-based vaccines. In order to home
to draining LN and subsequently activate speciWc T cells,
DC have to reach the correct level of activation and display
the correct set of chemokine receptors, expression of which
should be precisely orchestrated, both spatially and chrono-
logically [33]. In vitro generated and readministered DC do
not necessarily fulWll all these requirements, as only very
low numbers of injected DC (typically <1%) reach the
draining lymph nodes [7]. Therefore, next to improving
whole tumor cell and/or DC-based vaccines, direct in vivo
approaches certainly deserve more attention. Of note, many
novel tools have now become available for targeting DC
[49]. In parallel studies, therefore, we currently pursue the
latter approach using DC-targeting adenoviral vectors car-
rying antigenic payloads [5, 6, 54]. At the end of the day,
results from rigidly controlled and comparative clinical
studies should reveal those immunotherapeutic approaches
that deserve inclusion into regular cancer patient care.
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References
1. Baars A, Claessen AME, van den Eertwegh AJM, Gall HE, Stam
AG, Meijer S, Giaccone G, Meijer CJ, Scheper RJ, WagstaV J,Cancer Immunol Immunother (2008) 57:1569–1577 1575
123
Vermorken JB, Pinedo HM (2000) Skin tests predict survival after
autologous tumor cell vaccination in metastatic melanoma: expe-
rience in 81 patients. Ann Oncol 11:965–970
2. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet
N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N,
Pineiro L, Steinman R, Fay J (2001) Immune and clinical respons-
es in patients with metastatic melanoma to CD34(+) progenitor-
derived dendritic cell vaccine. Cancer Res 61:6451–6458
3. Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ (2004)
Immunopharmacologcal analysis of an autologous, hapten-modi-
Wed human melanoma vaccine. J Clin Oncol 22:403–415
4. Davis ID, JeVord M, Parente P, Cebon J (2003) Rational approach-
es to human cancer immunotherapy. J Leukoc Biol 73:3–29
5. de Gruijl TD, Luykx-de Bakker SA, Tillman BW, van den
Eertwegh AJ, Buter J, Lougheed SM, van der Bij GJ, Safer AM,
Haisma HJ, Curiel DT, Scheper RJ, Pinedo HM, Gerritsen WR
(2002) Prolonged maturation and enhanced transduction of den-
dritic cells migrated from human skin explants after in situ deliv-
ery of CD40-targeted adenoviral vectors. J Immunol 169:5322–
5331
6. de Gruijl TD, Ophorst OJ, Goudsmit J, Verhaagh S, Lougheed
SM, Radosevic K, Havenga MJ, Scheper RJ (2006) Intradermal
delivery of adenoviral type-35 vectors leads to high eYciency
transduction of mature, CD8+ T-Cell-stimulating skin-emigrated
dendritic cells. J Immunol 177:2208–2215
7. de Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ,
Diepstra JH, Van Muijen GN , Strijk SP, Ruers TJ, Boerman OC,
Oyen WJ, Adema GJ, Punt CJ, Figdor CG (2003) EVective migra-
tion of antigen-pulsed dendritic cells to lymph nodes in melanoma
patients is determined by their maturation state. Cancer Res
63:12–17
8. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby
ES, Gillis S, Cheever MA (1996) Granulocyte-macrophage
colony-stimulating factor: an eVective adjuvant for protein and
peptide-based vaccines. Blood 88:202–210
9. DranoV G, JaVee E, Lazenby A, Golumbek P, Levitsky H, Brose
K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vacci-
nation with irradiated tumor cells engineered to secrete murine
granulocyte-macrophage colony-stimulating factor stimulates po-
tent, speciWc, and long-lasting immunity. Proc Natl Acad Sci USA
90:3539–3543
10. DranoV G (2002) GM-CSF-based cancer vaccines. Immunol Rev
188:147–154
11. Eager R, Nemunaitis J (2005) GM-CSF gene-transduced tumor
vaccines. Mol Ther 12:18–27
12. Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into
its biological function and use in tumor immunotherapy. Nat
Immunol 3:611–618
13. Fabre JW (2001) The allogeneic response and tumor immunity.
Nat Med 7:649–652
14. Ferlazzo G, Wesa A, Wei WZ, Galy A (1999) Dendritic cells
generated either from CD34+ progenitor cells or from monocytes
diVer in their ability to activate antigen-speciWc CD8+ T-cells.
J Immunol 163:3597–3604
15. Fox JL (2007) Uncertainty surrounds cancer vaccine review at
FDA. Nat Biotech 25:827–828
16. Gerritsen WR, van den Eertwegh AJM, de Gruijl TD, Giaccone G,
Scheper RJ, Sacks N, Harding T, Lowy I, Stankevich E, Hege K
(2007) Biochemical and immunologic correlates of clinical re-
sponse in a combination trial of the GM-CSF-gene transduced
allogeneic prostate cancer immunotherapy and ipilimumab in
patients with metastatic hormone-refractory prostate cancer
(mHRPC). ASCO Meeting Abstr 25:5120
17. Hanna MG Jr, Peters LC (1978) Immunotherapy of established
micrometastases with a bacillus Calmette-Guerin tumour cell vac-
cine. Cancer Res 38:204–209
18. Hanna MG Jr, Brandhorst JS, Peters LC (1979) Active speciWc
immunotherapy of residual micrometastases: an evaluation of
sources, doses and ratios of BCG with tumour cells. Cancer Immu-
nol Immunother 7:165–173
19. Hanna MG, Hoover HC, Vermorken JB, Harris JE, Pinedo HM
(2001) Adjuvant active speciWc immunotherapy of stage II and
stage III colon cancer with an autologous tumour cell vaccine: Wrst
randomized phase III trials show promise. Vaccine 19:2576–2582
20. Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson
AB 3rd, Mansour E, Haller DG, Manola J, Hanna MG Jr (2000)
Adjuvant active speciWc immunotherapy for stage II and III colon
cancer with an autologous tumour cell vaccine: eastern coopera-
tive oncology group study E5283. J Clin Oncol 18:148–157
21. Hasebe H, Nagayama H, Sato K, Enomoto M, Takeda Y, Takah-
ashi TA, Hasumi K, Eriguchi M (2000) Dysfunctional regulation
of the development of monocyte-derived dendritic cells in cancer
patients. Biomed Pharmacother 54:291–298
22. Hege KM, Jooss K, Pardoll D (2006) GM-CSF gene-modiWed can-
cer cell immunotherapies: of mice and men. Int Rev Immunol
25:321–352
23. Holtl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C,
Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M (2005)
Allogeneic dendritic cell vaccination against metastatic renal cell
carcinoma with or without cyclophosphamide. Cancer Immunol
Immunother 54:663–670
24. Hoover HC Jr, Brandhorst JS, Peters LC, Surdyke MG, Takeshita
Y, Madariaga J, Muenz LR, Hanna MG Jr (1993) Adjuvant active
speciWc immunotherapy for human colorectal cancer: 6.5- year
median follow-up of a phase III prospectively randomized trial.
J Clin Oncol 11:390–399
25. Hu ZB, Ma W, Zaborski M, MacLeod R, Quentmeier H, Drexler
HG (1996) Establishment and characterization of two novel cyto-
kine-responsive acute myeloid and monocytic leukemia cell lines,
MUTZ-2 and MUTZ-3. Leukemia 10:1025–1040
26. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Green-
berg NM, Burg MB, Allison JP  (2000) Combination immunother-
apy of primary prostate cancer in a transgenic mouse model using
CTLA-4 blockade. Cancer Res 60:2444–2448
27. Hus I, Rolinski J, Tabarkiewicz J, Wojas K, Bojarska-Junak A,
Greiner J, Giannopoulos K, Dmoszynska A, Schmitt M (2005)
Allogeneic dendritic cells pulsed with tumor lysates or apoptotic
bodies as immunotherapy for patients with early-stage B-cell
chronic lymphocytic leukemia. Leukemia 19:1621–1627
28. JaVee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K,
Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC,
Lillemoe KD, O’Reilly S, Abrams RA, Pardoll DM, Cameron JL,
Yeo CJ (2001) Novel allogeneic granulocyte-macrophage colony-
stimulating factor-secreting tumour vaccine for pancreatic cancer:
a phase I trial of safety and immune activation. J Clin Oncol
19:145–156
29. Jager E, RinghoVer M, Dienes HP, Arand M, Karbach J, Jager D,
Ilsemann C, Hagedorn M, Oesch F, Knuth A (1996) Granulocyte-
macrophage-colony-stimulating factor enhances immune respons-
es to melanoma-associated peptides in vivo. Int J Cancer 67:54–62
30. Jocham D, Richter A, HoVmann L, Iwig K, Fahlenkamp D, Zak-
rewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wieters-
heim J, Doehn C (2004) Adjuvant autologous renal tumour cell
vaccine and risk of tumour progression in patients with renal-cell
carcinoma after radical nephrectomy: phase III, randomised con-
trolled trial. The Lancet 363:594–599
31. Krieg AM (2003) CpG motifs: the active ingredient in bacterial
extracts? Nat Med 9:831–835
32. Krieg AM (2006) Therapeutic potential of Toll-like receptor 9
activation. Nat Rev Drug Discov 5:471–484
33. Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor
CG, Adema GJ, Punt CJ (2008) Dendritic cell vaccines in1576 Cancer Immunol Immunother (2008) 57:1569–1577
123
melanoma: from promise to proof? Crit Rev Oncol Hematol [Epub
ahead of print]
34. Masterson AJ, Sombroek CC, de Gruijl TD, Graus YM, van der
Vliet HJ, Lougheed SM, van den Eertwegh AJ, Pinedo HM, Sche-
per RJ (2002) MUTZ-3, a human cell line model for the cytokine-
induced diVerentiation of dendritic cells from CD34+ precursors.
Blood 100:701–703
35. Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J,
Chakraborty P, Leader D, Whelan M, Pandha H (2005) Delayed
disease progression after allogeneic cell vaccination in hormone-
resistant prostate cancer and correlation with immunologic vari-
ables. Clin Cancer Res 11:4469–4478
36. Neves AR, Ensina LF, Anselmo LB, Leite KR, Buzaid AC,
Camara-Lopes LH, Barbuto JA (2005) Dendritic cells derived
from metastatic cancer patients vaccinated with allogeneic den-
dritic cell-autologous tumor cell hybrids express more CD86 and
induce higher levels of interferon-gamma in mixed lymphocyte
reactions. Cancer Immunol Immunother 54:61–66
37. Petrylak DP, Macarthur RB, O’Connor J, Shelton G, Judge T, Bal-
og J, PfaV C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I,
Benson M, Olsson CA (1999) Phase I trial of docetaxel with est-
ramustine in androgen-independent prostate cancer. J Clin Oncol
17:958–967
38. Ratzinger G, Baggers J, de Cos MA, Yuan J, Dao T, Reagan JL,
Munz C, Heller G, Young JW (2004) Mature human Langerhans
cells derived from CD34+ hematopoietic progenitors stimulate
greater cytolytic T lymphocyte activity in the absence of bioactive
IL-12p70, by either single peptide presentation or cross-priming
than do dermal-interstitial or monocyte-derived dendritic cells.
J Immunol 173:2780–2791
39. Santegoets SJAM, Schreurs MW, Masterson AJ, Liu YP, Goletz
S, Baumeister H, Kueter EW, Lougheed SM, van den Eertwegh
AJ, Scheper RJ, Hooijberg E, de Gruijl TD (2006a) In vitro prim-
ing of tumor-speciWc cytotoxic T lymphocytes using allogeneic
dendritic cells derived from the human MUTZ-3 cell line. Cancer
Immunol Immunother 55:1480–1490
40. Santegoets SJAM, Masterson AJ, van der Sluis PC, Lougheed SM,
Fluitsma DM, van den Eertwegh AJ, Pinedo HM, Scheper RJ, de
Gruijl TD (2006b) A CD34(+) human cell line model of myeloid
dendritic cell diVerentiation: evidence for a CD14(+) CD11b(+)
Langerhans cell precursor. J Leukoc Biol 80:1337–1344
41. Santegoets SJAM, Bontkes HJ, Stam AGM, Bhoelan F,
Ruizendaal JJ, van den Eertwegh AJM, Hooijberg E, Scheper RJ,
de Gruijl TD (2008) Inducing anti-tumor T-cell immunity: com-
parative functional analysis of interstitial versus Langerhans den-
dritic cells in a human cell line model. J Immunol 180:4540–4549
42. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley
PA, Hussain A, Small EJ, Vogelzang NJ (2001) Phase II study of
docetaxel, estramustine, low-dose hydrocortisone in men with hor-
mone-refractory prostate cancer: a Wnal report of CALGB 9780.
Cancer and Leukemia Group B. J Clin Oncol 19:2509–2516
43. Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM (2003)
Induction of speciWc antitumor immunity in the mouse with the
electrofusion product of tumor cells and dendritic cells. Mol Ther
7:498–505
44. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B,
Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S (2006)
Phase I/II trial of an allogeneic cellular immunotherapy in hor-
mone-naïve prostate cancer. Clin Cancer Res 12:3394–3401
45. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis
JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM (2006) Pla-
cebo-controlled phase III trial of immunologic therapy with sipu-
leucel-T (APC8015) in patients with metastatic, asymptomatic
hormone refractory prostate cancer. J Clin Oncol 24:3089–3094
46. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS,
Nelson WG, Ando D, Howard C, Borellini F, Nguyen M,
Hege K, Simons JW (2007) Granulocyte macrophage colony-
stimulating factor-secreting allogeneic cellular immunotherapy
for hormone-refractory prostate cancer. Clin Cancer Res 13:3883–
3891
47. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP
(2007) A pilot trial of CTLA-4 blockade with human anti-CTLA-
4 in patients with hormone-refractory prostate cancer. Clin Cancer
Res 13:1810–1815
48. Suzuki T, Fukuhara T, Tanaka M, Nakamura A, Akiyama K,
Sakakibara T, Koinuma D, Kikuchi T, Tazawa R, Maemondo M,
Hagiwara K, Saijo Y, Nukiwa T (2005) Vaccination of dendritic
cells loaded with interleukin-12-secreting cancer cells augments in
vivo antitumor immunity: characteristics of syngeneic and alloge-
neic antigen-presenting cell cancer hybrid cells. Clin Cancer Res
11:58–66
49. Tacken PJ, de Vries IJ, Torensma R, Figdor CG (2007) Dendritic-
cell immunotherapy: from ex vivo loading to in vivo targeting.
Nat Rev Immunol 7:790–802
50. Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J,
Tate P, Stamp G, Farzaneh F, Harrison P, Stauss H, George AJ,
Habib N, Lechler RI, Lombardi G (2007) Induction of tumor-speciWc
T-cell responses by vaccination with tumor lysate-loaded dendritic
cells in colorectal cancer patients with carcinoembryonic-antigen
positive tumors. Cancer Immunol Immunother 56:2003–2016
51. Tanaka Y, Koido S, Chen D, Gendler SJ, Kufe D, Gong J (2001)
Vaccination with allogeneic dendritic cells fused to carcinoma
cells induces antitumor immunity in MUC1 transgenic mice. Clin
Immunol 101:192–200
52. Tarr PE (1996) Granulocyte-macrophage colony-stimulating fac-
tor and the immune system. Med Oncol 13:133–140
53. Thompson RH, Allison JP, Kwon ED (2006) Anti-cytotoxic t lym-
phocyte (CTLA-4) immunotherapy for the treatment of prostate
cancer. Urol Oncol 24:442–447
54. Tillman BW, Hayes TL, de Gruijl TD, Douglas JT, Curiel DT
(2000) Adenoviral vectors targeted to CD40 enhance the eYcacy
of dendritic cell-based vaccination against human papillomavirus
16-induced tumor cells in a murine model. Cancer Res 60:5456–
5463
55. Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H,
Audring H, Guo Y, Sterry W, Walden P (2000) Hybrid cell vacci-
nation for cancer immune therapy: Wrst clinical trial with meta-
static melanoma. Int J Cancer 85:618–626
56. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M,
Sherev T, Sparbier K, Sterry W, Walden P (2004) Vaccination
with hybrids of tumor and dendritic cells induces tumor-speciWc
T-cell and clinical responses in melanoma stage III and IV
patients. Int J Cancer 110:730–740
57. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sha-
rav T, Sparbier K, Sterry W, Walden P (2005) Tumour-dendritic
hybrid cell vaccination for the treatment of patients with malignant
melanoma: immunological eVects and clinical results. Vaccine
23:2367–2373
58. Yasuda T, Kamigaki T, Kawasaki K, Nakamura T, Yamamoto M,
Kanemitsu K, Takase S, Kuroda D, Kim Y, Ajiki T, Kuroda Y
(2007) Superior anti-tumor protection and therapeutic eYcacy of
vaccination with allogeneic and semiallogeneic dendritic cell/tu-
mor cell fusion hybrids for murine colon adenocarcinoma. Cancer
Immunol Immunother 56:1025–1036
59. van den Eertwegh AJM, Lensen RJ, Scheper RJ, Giaccone G,
Meijer CJLM, Bontkes HJ, Gruijl TD, Hooijberg E (2006) Autol-
ogous tumor cell vaccination with PF-3512676 (CPG 7909) and
GM-CSF followed by subcutaneous PF-3512676 and IFN-alpha
for patients with metastatic renal cell carcinoma. ASCO Meeting
Abstr 24:2530
60. van Elsas A, Hurwitz AA, Allison JP (1999) Combination immu-
notherapy of B16 melanoma using anti-cytotoxic T lymphocyte-Cancer Immunol Immunother (2008) 57:1569–1577 1577
123
associated antigen 4 (CTLA-4) and granulocyte/macrophage col-
ony-stimulating factor (GM-CSF)-producing vaccines induces
rejection of subcutaneous and metastatic tumors accompanied by
autoimmune depigmentation. J Exp Med 190:355–366
61. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J,
Medema JP, Overwijk WW, Restifo NP, Melief CJM, OVringa R,
Allison JP (2001) Elucidating the autoimmune and antitumor
eVector mechanisms of a treatment based on cytotoxic T lympho-
cyte antigen-4 blockade in combination with a B16 melanoma
vaccine: comparison of prophylaxis and therapy. J Exp Med
194:481–489
62. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R,
Meijer S, Scheper RJ, Meijer CJLM, Bloemena E, Ransom JH,
Hanna MG Jr, Pinedo HM (1999) Active speciWc immunotherapy
for stage II and stage III human colon cancer: a randomised trial.
Lancet 353:345–350
63. Anonymous (2008) The regulator disapproves. Nat Biotechnol
26:1